Leerink Swann set a $26.00 price objective on Amarin (NASDAQ:AMRN) in a report published on Tuesday morning, TipRanks reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other brokerages have also weighed in on AMRN. HC Wainwright reiterated a buy rating on shares of Amarin in a research report on Thursday, August 1st. Roth Capital set a $31.00 price objective on Amarin and gave the stock a buy rating in a research report on Friday, September 6th. Cantor Fitzgerald set a $35.00 price objective on Amarin and gave the stock a buy rating in a research report on Tuesday, September 3rd. Svb Leerink initiated coverage on Amarin in a research report on Wednesday, August 14th. They issued an outperform rating and a $26.00 price objective for the company. Finally, Jefferies Financial Group set a $30.00 price objective on Amarin and gave the stock a buy rating in a research report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Amarin presently has a consensus rating of Buy and an average price target of $29.50.
Shares of AMRN stock traded up $0.08 during trading hours on Tuesday, reaching $16.75. The company had a trading volume of 30,117 shares, compared to its average volume of 6,576,359. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.76 and a current ratio of 2.01. The stock has a fifty day moving average of $16.08 and a 200-day moving average of $18.42. The company has a market capitalization of $5.83 billion, a price-to-earnings ratio of -42.87 and a beta of 1.27. Amarin has a 12-month low of $2.65 and a 12-month high of $23.91.
Amarin (NASDAQ:AMRN) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01. The business had revenue of $100.40 million during the quarter, compared to analyst estimates of $99.54 million. Amarin had a negative return on equity of 111.75% and a negative net margin of 27.51%. The business’s revenue was up 90.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.10) earnings per share. On average, analysts forecast that Amarin will post -0.2 EPS for the current year.
In other news, Director Joseph S. Zakrzewski sold 100,000 shares of the stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $19.02, for a total value of $1,902,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Lars Ekman sold 91,016 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $15.01, for a total value of $1,366,150.16. Following the completion of the sale, the director now owns 13,500 shares in the company, valued at $202,635. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 659,202 shares of company stock valued at $13,058,754. Company insiders own 2.75% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Wealthcare Advisory Partners LLC acquired a new stake in shares of Amarin in the first quarter valued at $42,000. Kistler Tiffany Companies LLC raised its stake in Amarin by 166.7% in the second quarter. Kistler Tiffany Companies LLC now owns 2,400 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 1,500 shares in the last quarter. Tobam raised its stake in Amarin by 45.5% in the second quarter. Tobam now owns 3,200 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 1,000 shares in the last quarter. Global Retirement Partners LLC raised its stake in Amarin by 30.7% in the first quarter. Global Retirement Partners LLC now owns 3,414 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 802 shares in the last quarter. Finally, Quantamental Technologies LLC acquired a new stake in Amarin in the second quarter valued at $74,000. Institutional investors and hedge funds own 47.94% of the company’s stock.
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.
Recommended Story: How is Preferred Stock Different from Common Stock?
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.